Hosted by Martin Slezak and Simon Birksø · 🇺🇸 US · EN-US · 19 episodes
Established thought leaders with verified media credentials.
Hello and welcome to Cures & Capital - the podcast on value creation in biotech and pharma. Together, we are going to dive deep into the world of biotech and pharma to tackle the holy grail - how do we improve return on investment from drug innovation and deliver transformative therapies to patients, efficiently and sustainably. Hosted by Martin Slezak & Simon Birksø Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.
Martin Slezak and Simon Birksø hosts Cures & Capital, a business show with 19 episodes published.
In this episode, we speak with Jan Lundberg – former President of Lilly Research Laboratories and Head of R&D at Eli Lilly and Company. With a career spanning academia, biotech, and big pharma, Jan has contributed to the
How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients acro
In this episode of Cures & Capital, Dr. Sheila Gujrathi — biotech entrepreneur, investor, and former CEO of Gossamer Bio — shares her perspective on how to elevate female leaders and underrepresented voices in biopharma.
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials
In this episode, we talk to Deborah Dunsire, board chair at Neurvati Neurosciences, multiple times board member, and a former CEO of Lundbeck. With more than 3 decades of experience, Deborah has navigated organizations o
In this episode, we talk to Dr. Andrée Bates, founder and CEO of Eularis, a company helping clients accelerate pharma business results through Artificial Intelligence. We explore how the biopharma industry can move beyon
How did China become a serious force in global biotech in just over a decade? This is the insider story of China's biotech boom! Dr. Leon 'Jun' Tang, founding partner of InScienceWeTrust BioAdvisory, joins Cures & Capita
In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches. This conversation is a practical guide to new drug launches, packed with
In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches. This conversation is a practical guide to new drug launches, packed with
Over the past few months, we’ve had the chance to speak with some of the sharpest minds in the industry—thinkers and practitioners who have shaped how we understand drug innovation, R&D productivity, portfolio strategy,
In this episode, we talk to Aaron Schact, the CEO and Board Director at BiomEdit and former R&D leader at Eli Lilly and Elanco. We discuss how to improve biopharma's R&D productivity and the industry's "grand challenge",
In this episode, our guest is Dr. Matthias Krings - a senior partner at Catenion, a biopharma strategy consulting firm. Matthias is a seasoned veteran in biopharma strategy. In this conversation, he shares his playbook f
How do venture capitalists think? And how do they define and create value in the life science industry? In this episode, we talk to Stephan Christgau, founding partner of Eir Ventures, about the VC mindset, investment de
In this episode, we sit down with Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, to discuss the trends shaping the life sciences industry in 2025 and beyond. How do we navigate the life
In this episode, Mike Rea - CEO, IDEA Pharma - takes us on a journey through innovation and value creation in pharma. It is not all roses! He shares his candid views on what the pharmaceutical industry needs to do better
In this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innova
In this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more. If you're looking to deepen your understanding of these areas, there's no better guide than Jack.
EPISODE 1 - Cures & Capital: Trailer Episode In this episode, we introduce the scope and mission of the podcast. Our focus with Cures & Capital is the intersection between drug R&D and finance. Hosts: Martin Slezak & Sim
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Cures & Capital, visit https://curesandcapital.buzzsprout.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent business coverage.
Cures & Capital is hosted by Martin Slezak and Simon Birksø. The show is categorised under business and has published 19 episodes.
Cures & Capital has published 19 episodes.
Cures & Capital regularly covers business. It sits in the business category.
Cures & Capital is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Cures & Capital hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Cures & Capital average 60 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Cures & Capital's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.
